Chemotherapy-Induced Peripheral Neuropathy (CIPN): Market View, Current and Future Competitive Landscape

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3495
Buy Report Download FREE Resources

Published: March 19, 2026 Report Code: GDHC023MV-ST

Select Item

Understand the Chemotherapy-Induced Peripheral Neuropathy (CIPN) therapeutics market with insights into pipeline drugs, clinical trials, epidemiology, pricing, reimbursement, competitive benchmarking, and future market opportunities. Explore GlobalData’s data-driven CIPN market analysis and forecast intelligence.

CIPN Market Forecast, Clinical Trial Activity, and Competitive Intelligence

GlobalData’s Chemotherapy-Induced Peripheral Neuropathy (CIPN) report delivers a data-driven overview of the current and future competitive landscape within the CIPN therapeutics market.

The report highlights key trends across epidemiology, pipeline development, clinical trials, pricing and reimbursement, commercial activity, and future market catalysts. In addition, it provides insight into marketed therapies, emerging treatment approaches, and competitive positioning across the global market.

China is anticipated to account for the highest number of diagnosed incident CIPN cases in both 2024 and 2029, representing a significant portion of global cases. However, the market currently has no disease-modifying therapies or nerve regenerative strategies capable of halting nerve damage, promoting regeneration, or reversing established neuropathy.

The pipeline currently contains 60 molecules, including four Phase III assets and 11 Phase II assets. Over the past decade, 218 clinical trials were conducted in CIPN, with 2022 recording the highest number of initiated studies at 35 trials.

Built using GlobalData’s Pharma Intelligence Center and in-house analyst expertise, this report helps you evaluate pipeline opportunities, benchmark competitors, and understand future market dynamics shaping the CIPN therapeutics landscape.

Report Value Proposition – Why This Matters for You

This report helps you assess where future opportunities may emerge within the Chemotherapy-Induced Peripheral Neuropathy therapeutics market.

You can use the analysis to evaluate pipeline maturity, understand clinical development activity, assess reimbursement and pricing dynamics, and identify companies advancing innovative therapeutic strategies.

In addition, the report combines epidemiology data, clinical trial analytics, commercial assessments, and pipeline forecasting into a single strategic resource. This may help support licensing decisions, investment planning, commercial strategy development, and competitive benchmarking.

The report also highlights market gaps and unmet needs, which remain significant due to the absence of disease-modifying or nerve regenerative therapies.

Key Insights in the Chemotherapy-Induced Peripheral Neuropathy Therapeutics Market

  • China is expected to account for the highest number of diagnosed incident CIPN cases in both 2024 and 2029.
  • The current market lacks disease-modifying therapies and regenerative treatment strategies.
  • The CIPN pipeline includes 60 molecules under development.
  • Four assets are currently in Phase III development, while 11 assets are in Phase II.
  • Over the past decade, 218 clinical trials have been conducted in CIPN.
  • The highest number of studies initiated occurred in 2022, with 35 clinical trials.
  • No products are currently in the pre-registration stage.
  • The report includes pipeline, pricing, reimbursement, and commercial analysis.

Scope

What You Will Learn

  • Current and future competitive landscape within the CIPN therapeutics market

  • Epidemiology trends and diagnosed incident case analysis

  • Pipeline breakdown by development stage, mechanism of action, molecule type, and route of administration

  • Marketed product assessments and sales forecasts

  • Pricing and reimbursement trends, including annual therapy cost analysis

  • Clinical trial activity by geography, phase, sponsors, enrollment, and endpoints

  • Commercial assessment of key market participants and future market catalysts

  • Recent mergers, acquisitions, and strategic alliance activity within the market

Target Buyers for This Report

This report may support strategic planning and market evaluation for:

  • Pharmaceutical companies developing neurology or oncology supportive care therapies

  • Biotechnology firms advancing neuropathy treatment pipelines

  • Clinical development and translational medicine teams

  • Licensing and business development professionals

  • Commercial strategy and market access teams

  • Healthcare consulting and advisory firms

  • Institutional investors and private equity firms evaluating therapeutic markets

  • Competitive intelligence and forecasting teams

How Companies Use This Report

Healthcare companies may use this report to evaluate pipeline positioning, assess future competition, and identify areas of unmet need within the CIPN therapeutics market.

For example:

  • Pharmaceutical companies may use the report to benchmark pipeline assets against competing therapies and emerging mechanisms of action.

  • Biotech firms may evaluate clinical trial activity and likelihood of approval to support partnership or licensing decisions.

  • Investors and strategic advisory firms may use epidemiology forecasts and commercial assessments to identify growth opportunities.

  • Commercial teams may use pricing and reimbursement analysis to support launch planning and market access strategies.

In addition, organizations can use the report to benchmark against global leaders and emerging innovators active within the CIPN therapeutics landscape.

Reasons to Buy

Benchmark Against Emerging and Established Market Participants

The report provides insight into marketed products, late-to-mid-stage pipeline therapies, and commercial positioning across the global CIPN therapeutics market.

Moreover, the combination of pipeline intelligence, clinical trial analytics, and commercial assessments may help organizations benchmark development strategies and identify competitive differentiation opportunities.

Built on Trusted GlobalData Pharma Intelligence

Built using GlobalData’s Pharma Intelligence Center and supported by in-house analyst expertise, this report combines epidemiology analysis, pipeline tracking, clinical trial intelligence, pricing assessments, and commercial forecasting into one strategic resource.

The analysis may help support business development planning, licensing evaluations, market forecasting, and competitive benchmarking across the evolving CIPN therapeutics landscape.

Trusted by pharmaceutical companies, investors, and healthcare strategy teams worldwide, GlobalData’s research provides insight into emerging therapeutic opportunities and competitive market dynamics.

Act Now to Evaluate Emerging Opportunities in the CIPN Therapeutics Market

As clinical development activity continues and companies pursue innovative approaches to addressing unmet needs in Chemotherapy-Induced Peripheral Neuropathy, organizations require reliable market intelligence to support strategic decision-making.

This report provides the data, competitive analysis, and pipeline insight needed to evaluate future market opportunities, benchmark competitors, and monitor evolving therapeutic trends within the global CIPN market.

Table of Contents

Table of Contents (PowerPoint Deck)

1 Preface

1.1 Contents

1.2 Report Scope

1.3 List of Tables and Figures

1.4 Abbreviations

2 Key Findings

3 Disease Landscape

3.1 Disease Overview

3.2 Epidemiology Overview

3.3 Treatment Overview

4 Marketed Drugs Assessment

4.1 Leading Marketed Drugs

4.2 Overview by Mechanism of Action

4.3 Overview by Molecule Type

4.4 Product Profile and Sales Forecast

5 Pricing and Reimbursement Assessment

6 Pipeline Drugs Assessment

6.1 Pipeline Drugs

6.2 Overview by Development Stage

6.3 Overview by Mechanism of Action

6.4 Overview by Molecule Type

6.5 Product Profile and Sales Forecast

6.6 Drug-specific PTSR and LoA

6.7 Indication-specific and Therapy Area-specific PTSR and LoA

7 Clinical Trials Assessment

7.1 Historical Overview

7.2 Overview by Phase

7.3 Overview by Status

7.4 Overview by Phase for Ongoing and Planned Trials

7.5 Trials with Virtual Components

7.6 Top 20 Biomarkers by Trial Phase

7.7 Overview of Trials by Geography

7.8 Single-Country and Multinational Trials by Region

7.9 Top 20 Sponsors with Breakdown by Phase

7.10 Top 20 Sponsors with Breakdown by Status

7.11 Overview by Endpoint Status

7.12 Overview by Race and Ethnicity

7.13 Enrollment Data

7.14 Top 20 countries for Trial Sites

7.15 Top 20 Sites Globally

7.16 Feasibility Analysis – Geographic Overview

7.17 Feasibility Analysis – Benchmark Models

8 Deals Landscape

8.1 Mergers, Acquisitions, and Strategic Alliances by Region

8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

11.1 Methodology

11.2 Methodology – Sales Forecast

11.3 Methodology – Pricing and Reimbursement

11.4 Methodology – PTSR and LoA Analysis

11.5 About the Authors

11.6 Contact Us

11.7 Disclaimer

Chemotherapy-Induced Peripheral Neuropathy (CIPN): Market View, Current and Future Competitive Landscape standard reports
Currency USD
$3,495

Can be used by individual purchaser only

Most Popular
$6,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$10,485

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Chemotherapy-Induced Peripheral Neuropathy (CIPN): Market View, Current and Future Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Chemotherapy Induced Peripheral Neuropathy reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Pharmaceuticals
New
Overweight and Obesity: Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Chemotherapy-Induced Peripheral Neuropathy (CIPN): Market View, Current and Future Competitive Landscape in real time.

  • Access a live Chemotherapy-Induced Peripheral Neuropathy (CIPN): Market View, Current and Future Competitive Landscape dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more